Derm News: 2007.24(4)

Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety

Journal of the American Academy of Dermatology, 56(4):604-611
Nicholas J. Lowe, Dee Anna Glaser, Nina Eadiec, Simon Daggett, Jonathan W. Kowalski, Pan-Yu Lai
ABSTRACT

Background

The long-term effects of botulinum toxin type A (BoNTA) on the global impairment associated with severe primary axillary hyperhidrosis have not been comprehensively assessed relative to placebo.

Objectives

To assess the efficacy and safety of 2 dosages of BoNTA compared with placebo in subjects with primary axillary hyperhidrosis.

Methods

Subjects (N = 322) were randomized to the use of BoNTA (75 U or 50 U/axilla) or placebo in this 52-week, multicenter, double-blind study.

Results

BoNTA treatment significantly reduced daily activity limitations at 4 weeks after injection. A 2-point improvement on the 4-point Hyperhidrosis Disease Severity Scale (HDSS) was reported in 75% of subjects in the 75-U and 50-U BoNTA groups and in 25% of the placebo group (P < .001). Improvements in HDSS scores were corroborated by gravimetric results. The median duration of effect was 197 days, 205 days, and 96 days in the 75-U, 50-U, and placebo groups, respectively. BoNTA was well tolerated.

Limitations

The effect of total surface area involvement on treatment efficacy was not evaluated.

Conclusions

BoNTA treatment effectively reduces the symptoms of primary axillary hyperhidrosis and is well tolerated.

    Back to Current Volume:   Dermatology News 2007.24

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.